cell therapy

Researchers have found that certain pancreatic cells can be converted into insulin-producing beta cells with a single genetic modification, according to a Wired report. The finding suggests a potential new avenue for treating diabetes by reprogramming cells already present in the pancreas, and it is drawing attention from readers following advances in regenerative medicine and genetic engineering.

Researchers at UMass Chan Medical School report that lupus patients treated with CAR T cell therapy have remained free of disease flares two years after receiving the one-time cell-based treatment. The therapy, originally developed for blood cancers, reprograms a patient's own immune cells, and the latest follow-up data suggest it may offer lasting remission in autoimmune disease.

A new study in Nature reports that cell-free RNA found in urine can be used to detect bladder cancer and predict how patients respond to treatment. The liquid biopsy approach could offer a non-invasive alternative to cystoscopy, potentially enabling earlier diagnosis and closer monitoring of therapy response without invasive procedures.

UConn Health has announced the launch of a new CAR-T cell therapy program, a form of immunotherapy that engineers a patient's own immune cells to fight cancer. The initiative brings an advanced, personalised cancer treatment to the Connecticut institution, expanding access for patients in the region who previously had to travel elsewhere for such therapy.

Imaavy (nipocalimab-aahu) has become the first approved treatment for warm autoimmune hemolytic anemia, a rare condition in which the immune system destroys red blood cells. Observers in the science and biotech community are calling it a significant win for the treatment of orphan diseases, noting that patients with wAIHA previously had no approved dedicated therapy. Approval of a drug for such a small patient population highlights growing momentum in rare disease drug development.

A study suggests that pomegranates, walnuts and berries could hold the key to a new treatment for heart failure. These foods prompt the gut to produce urolithin A, a compound that supports the energy function of heart cells. Early findings indicate the compound may help improve cardiac performance, though researchers caution that human trials are still needed before firm conclusions can be drawn.

A hospital in Japan has performed the world's first surgery using sheets of commercially available heart muscle stem cells, according to one of the surgeons involved. The groundbreaking therapy was approved earlier this year, and this operation marks the first time the ready-made cell sheets have been used in a patient. The procedure is being seen as a significant step for regenerative medicine in treating heart disease.

Anitocabtagene autoleucel, a cell therapy, is associated with sustained clinical responses in patients with heavily pretreated multiple myeloma, according to a report in medical news. The finding is notable for a disease where patients who have exhausted standard lines of treatment typically face poor outcomes. Clinicians are watching whether such CAR-T approaches can extend durable remissions.

Scientists report a potential way to stop cancer-fighting T cells from burning out, a key limitation in immunotherapy treatments. When T cells become exhausted during prolonged battles with tumors, they lose their ability to kill cancer cells effectively. The newly reported finding could improve therapies that rely on reprogramming a patient's immune cells, and researchers say it may open new avenues for making cancer immunotherapies last longer.

A study published in Nature Medicine reports that Resero Bio's cell-free RNA platform can detect bladder cancer and predict how patients respond to treatment. The findings, picked up by financial and science media, suggest the technology could support earlier diagnosis and better-targeted therapy decisions in bladder cancer care, one of the most common and recurrent urological cancers.

Florida Atlantic University has received a grant from the National Institutes of Health to study newly identified cells that may help repair nerve damage. The funding will support research into how these cells work and whether they could lead to new treatments for nerve injuries, an area where effective therapies remain limited.

Researchers have reported the development of a synthetic lethal drug aimed at cancers with microsatellite instability, a genetic feature found in colorectal and other tumor types. Synthetic lethality exploits mutations unique to cancer cells, sparing healthy tissue. The work was published in Nature, and scientists say such drugs could expand treatment options for patients whose tumors resist existing immunotherapies.

Young patients treated at RWJBarnabas Health are celebrating being disease-free after receiving advanced treatments for sickle cell disease. The health system highlighted the milestone, pointing to newer therapies that can significantly alter the course of the inherited blood disorder, which disproportionately affects Black and Hispanic children and often causes lifelong pain crises and organ damage.

Researchers have developed a new mathematical model that tracks how the tumor microenvironment influences the effectiveness of cancer therapies. By capturing interactions between tumor cells and their surroundings, the model aims to help predict which treatments will work for individual patients and guide the design of combination therapies.

Yale School of Medicine is highlighting advances in CAR-T therapy, a treatment that engineers a patient's immune cells to fight disease. Originally developed for blood cancers, the approach is now being adapted and studied for autoimmune conditions, marking a significant expansion of its potential use in medicine.

Technology Networks reports that advanced cell models are accelerating progress in precision medicine. The piece describes how improved laboratory models of human cells and tissue allow therapies to be tested against a patient's specific biology, supporting more tailored diagnosis and treatment and moving personalised approaches from promise into clinical practice.

Researchers report that changing the metabolism of heart cells can unlock an inherent self-repair mechanism following a heart attack. The finding suggests a potential new route to regenerating damaged heart tissue, a long-standing goal in cardiology since adult heart muscle repairs itself poorly. Details of the study, including the model used and clinical implications, were not provided.

Spanish biotech Aptadir has secured a €40 million funding package to advance its demethylating medicines, a class of therapies targeting epigenetic changes in cancer cells. The company says the new capital will support development of its pipeline of epigenetic drug candidates as it moves toward clinical progress.